MedTrace Logo

A Study of HQK-1001 in Patients With Sickle Cell Disease

NCT01322269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2013-06-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.

Conditions

Interventions

DRUG

HQK-1001

HQK-1001 tablets, once daily for daily 26 weeks

Sponsors & Collaborators

  • HemaQuest Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Ghalie, MD, MBA · HemaQuest Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-03-31

Countries

  • United States
  • Canada
  • Egypt
  • Jamaica
  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01322269 on ClinicalTrials.gov